Pharmaceutical manufacturer for Sodium hydroxide

The Ajinomoto Group has advanced its purpose from “Unlocking the power of amino acids to resolve the food and health issues” to “contributing to the well-being of all human beings, our society and our planet with ‘AminoScience’.” We consider well-being to mean health and happiness. Our advanced purpose therefore represents our commitment to achieving two outcomes by 2030 which are connected by food systems: to reduce our environmental impact by 50% and to help extend the healthy life expectancy of 1 billion people.

Actylis originated in September 2022 through the consolidation of eight well-established specialized manufacturing enterprises and three procurement companies, unified into a singular entity. The companies comprising Actylis are Aceto, A&C, A&C Bio Buffer, Cascade Chemistry, Finar, Interactifs, Islechem, Pharma Waldhof, Syntor Fine Chemicals, Biotron, and Talus. Actylis stands as a prominent producer and provider of essential raw materials and performance components for the Life Sciences, Specialized Chemicals, and Agriscience sectors.

BioSpectra produces top-quality GMP biological buffers and denaturants in a dedicated, USFDA-registered GMP facility. Additionally, they provide GMP small molecule synthesis, solvent and solution compounding, and purification of critical GMP process fine chemicals in various quantities. With a commitment to quality and compliance, their goal is to be a trusted partner in the secure supply chain and a solution for any key ingredient issues. The company focuses on small molecule synthesis and multistep purification for both traditional and bio-pharmaceutical applications, offering contract GMP product development and ongoing commercial manufacturing with full regulatory support.

Since its establishment in 1944, our company has been actively engaged in societal contributions as a comprehensive manufacturer of reagents. We are dedicated to creating products that cater to customer requirements and delivering high-quality reagents. Apart from a diverse range of general reagents, our inventory encompasses pharmaceutical intermediates, specialty chemicals, and clinical reagents for life science, all developed using our proprietary technologies derived from reagent manufacturing processes. Additionally, we are undertaking the development of reagents for genetics and regenerative medicine, with our product count already surpassing 50,000.